Steroid-refractory PD-(L)1 pneumonitis: incidence, clinical features, treatment, and outcomes.

ABSTRACT:

Background

Immune-checkpoint inhibitor (ICI)-pneumonitis that does not improve or resolve with corticosteroids and requires additional immunosuppression is termed steroid-refractory ICI-pneumonitis. Herein, we report the clinical features, management and outcomes for patients treated with intravenous immunoglobulin (IVIG), infliximab, or the combination of IVIG and infliximab for steroid-refractory ICI-pneumonitis.

Methods

Patients with steroid-refractory ICI-pneumonitis were identified between January 2011 and January 2020 at a tertiary academic center. ICI-pneumonitis was defined as clinical or radiographic lung inflammation without an alternative diagnosis, confirmed by a multidisciplinary team. Steroid-refractory ICI-pneumonitis was defined as lack of clinical improvemen

SUBMITTER: Balaji A 

PROVIDER: S-EPMC7797270 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature